

## 參考文獻

1. 陳拱北、吳新英、葉金川、鄭玉娟 1968-1976. 台灣地區及其他分類地區 別各種癌症死亡率彩色圖 台北：行政院國家科學委員會。
2. 鄭雅文 87 學年度 中草藥對引發癌細胞細胞程式凋亡及抑制生長之研究 國立陽明大學生物藥學研究所碩士論文
3. Folkman J. 1990. What is the evidence that tumors are angiogenesis dependent? *J. Natl Cancer Inst.* 82,4~6
4. Gabriele B., Kashi J., Kin-Ming Lo, et al. 1999. Effect of angiogenesis inhibitors on multistage carcinogenesis in mice. *Science* 284,808~812
5. Hayes A.J., Li L.Y., Lippman M.E. 1999. science, mwdicine, and the future. Antivascular therapy: a new approach to cancer treatment. *BMJ* 318,853~856
6. Vander, Sherman, Luciano 1994. human physiology. international sixth edition 429~444
7. Roberto M., Jesus V.S., Katherine M.M., et al. 1998. Differential effects of hepatocyte growth factor isoforms on epithelial and endothelial tubulogenesis. *Cell Grow. Different.* 9,355~365
8. Hua L., Mohanraj D., Ruediger V., et al. 1999. Kringle 5 causes cell cycle arrest and apoptosis of endothelial cells. *Biochem. Biophys. Res. Communi.* 258,668~673
9. Clement B., Musso O., Lietard J. et al. 1999. Homeostatic control of angiogenesis: A newly identified function of the liver. *Hepatology* 29,621~623
10. 謝文全重輯 1995. 神農本草經(古今功能輯注本) 中國藥學研究所 第 20 味藥
11. 馬繼興 1995.12 神農本草經輯注北京人民衛生出版社 215~216
12. 王筠默、王恒芬 1988. 神農本草經校証 吉林科學技術出版社 303~304
13. 尚志鈞輯校 1986.6 名醫別錄 115~116
14. 陶弘景校注 1987.2 本草經集注 南大阪印刷 59
15. 岡西為人 1964.4 重輯新修本草 國立中國醫藥研究所 197

16. 盧多遜、李昉 尚志鈞輯校 1998.5 開寶本草(輯複本) 安徽科學技術出版社 184
17. 謝文全、李一宏 1989. 重輯嘉祐補註神農本草 中國藥學研究所 86~87
18. 謝文全 1993.12 重輯圖經本草 中國藥學研究所 293~294
19. 唐慎微 重修政和經史證類備用本草 卷八 草部中品之上(古書)
20. 唐慎微 1993.5 重修政和經史證類備用本草 華夏出版社 230
21. 唐慎微 1986.6 經史證類大觀本草 中國藥學研究所 228~229
22. 李時珍 明 1994. 本草綱目 中醫古籍出版社 340~342
23. 李時珍 明 1995. 本草綱目 重慶大學出版社 67
24. 吳其濬 清 1974. 植物名實圖考長編 世界書局 348~349
25. 陳嘉謨 明 1988. 本草蒙筌 人民衛生出版社 80~81
26. 陳士鐸 清 1996.7 本草新編 中國中醫藥出版社 124~125
27. 嚴潔 清 1997.12 得配本草 中國中醫藥出版社 48~49
28. 張璐撰 清 1996.7 本經逢原 北京中國中醫藥出版社 45~46
29. 沙世炎、徐禮燊等編 1982.3 中草藥有效成分分析法人民衛生出版社 211~213
30. 國家中醫藥管理局 1998.1 中華本草(精選本) 上海科學技術出版社 1682~1694
31. Motoo Y. & Sawabu N. 1994. Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. *Cancer Lett.* 86,91~95
32. 盧宏民撰 本草藥性大辭典 73.3 五州出版社 409~413
33. Tang W., Eisenbrand G. 1992. Chinese drugs of plant origin. (chemistry, pharmacology, and use in traditional and modern medicine) 919~929
34. 賴妙英 1999. 黃芩煎劑中黃芩在人體之口服吸收 中國醫藥學院中國藥學研究

所碩士論文

35. Muto R., Motozuka T., Nakano M., et al. 1998. The chemical structure of new substance as the metabolite of baicalin and time profiles for the plasma concentration after oral administration of Sho-Saiko-To in human. *Yakugaku-Zasshi* 118,79~87
36. 抗癌中草藥 1987.8 啟業書局 129~132
37. Ryu S.H., Ann B.Z., Pack M.Y. 1985. The cytotoxic principle of *Scutellariae radix* against L1210 cell. *Planta Med.* 5,462
38. Yuko M., Norie K., Shuji T. 1996. Cell death induced by baicalein in human hepatocellular carcinoma cell lines. *Jpn. J. Cancer Res.* 87,170~177
39. Huang H.C., Wang H.R., Hsieh L.M. 1994. Antiproliferative effect of baicalein, a flavonoid from a chinese herb, on vascular smooth muscle cell. *Eur. J. Pharmacol.* 251,91~93
40. Lodish H., Baltimore D., Berk A., et al. 1995. Molecular cell biology. Scientific american books third edition (Chapter 5 Cell division and the cell cycle) 177~185
41. Krtolica A., Krucher NA., Ludlow JW. 1999. Molecular analysis of selected cell cycle regulatory proteins during aerobic and hypoxic maintenance of human ovarian carcinoma cells. *Br-J-Cancer* 80,1875~83
42. Polyak K., Lee M.H., Koff A. et al. 1994. Cloning p27<sup>KIP1</sup>, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. *Cell* 78,59~66
43. 行政院衛生署中醫藥委員會 1999. 中醫藥年報 第十七期第三冊 555~598
44. 楊家駱 1974.4 植物名實圖考 世界書局 卷七 山草類 165~166
45. 韓維恒主編 1993.12 中藥正別名集 湖南科學技術出版社 171~173
46. 重修政和經史證類備用本草 卷八 草部中品之上(古書)
47. 劉嘉朝主編 1993.12 中藥研究文獻摘要第五卷 中國醫藥科學技術出版社 1020~1027
48. 楊繼祥主編 1993.5 藥用植物栽培學 農業出版社 40
49. 中國醫藥科學院藥物研究所 1993.1 中藥志( ) 人民衛生出版社 546~555
50. 周榮漢主編 1993. 中藥資源學 中國醫藥科學技術出版社 453~457

51. 海峽兩岸植物多樣性與保育學術研討會 議程論文摘要 1997.11.12 國立自然科學博物館 13,22~23
52. 謝文全 1995.7 神農本草經之考察與重輯 中國醫藥學院中國藥學研究所博士論文
53. 行政院衛生署中醫藥委員會 1985.10.10 中華民國中藥典範第一輯附錄 中藥典編輯委員會 91~94
54. 崔毅民 1978.6 本草集成 建豐彩色印刷公司 200~201
55. 裴鑒 1973.10 中國藥用植物誌 宏業書局 902~904
56. 楊見瑞等 1987.3 祁州中藥志 河北科學技術出版社 100~101
57. 謝宗萬編著 1994.11 中藥材品種論述(中冊) 上海科學技術出版社 550~556
58. 現代本草中國藥材學(上冊) 1974. 啟業書局印行 637~640
59. 中醫藥學 1985.12 南京藥學院 江蘇科學技術出版社 143~145
60. 徐國鈞等編 1996.10 中國藥材學(上) 中國醫藥科技出版社 398~402
61. 陳德華、王君根主編 1994.3 中藥的質量及其合理應用江蘇科學技術出版社 268~270
62. 謝文全、甘偉松 1997.9 藥用植物學 國立中國醫藥學研究所 487
63. 行政院衛生署中醫藥委員會 1985.10.10 中華民國中藥典範第一輯第一冊 中藥典編輯委員會 77~80
64. 郭南、張筑君 1993.12 常用中藥鑒定大全 黑龍江科學技術出版社 728~731
65. 楊曉穗編著 1994.5 常用中藥材真偽理化鑒別 中國醫藥科學技術出版社

138~143

66. 陳忠川 1999.6 中藥材品質管制-組織型態鑑定 行政院衛生署中醫藥委員會  
356~357
67. 那琦 1982. 黃芩之剖見 台灣藥學雜誌第十一卷第一期 43~45
68. 中醫藥學年報 1998.5 行政院衛生署中醫藥委員會編印 台北 12~15
69. 宋萬志等編 1995.5 常用中藥材品種整理和質量研究(北方編)第二冊 中國醫藥  
科學院藥物研究所 795~838
70. 陰健、郭力弓主編 1995.6 中藥現代研究與臨床應用 學苑出版社 559~569
71. 中藥藥學 1985.12 南京藥學院 江蘇科技出版社 143~145
72. 肖崇原主編 1987.11 中藥化學 上海科學技術出版社 245~247
73. 楊云、馮衛生 1998.8 中藥化學成分提取分離手冊 中國醫藥科技出版社 北京  
295~297
74. 許鴻源 1980.5 中藥材之研究 新醫藥出版社 22~24,568,566~567,725~726
75. 臺灣藥學雜誌 1982. 第三十四卷第二期 國立台灣師範大學化學研究所  
179~185,276~282(Journal of the Taiwan Pharmaceutical Association Vol. 34 No. 2  
1982)
76. 駱和生 1987.7 中藥與免疫(清熱類藥) 廣東科學技術出版社 1~3,5~13
77. 高木敬次郎著 1982.4 和漢藥物學 國立中國醫藥研究所 87~90
78. 謝明村等編 1988. 中國藥材學 中國醫藥學院協編 正中書局印行 171~174
79. 顏正華 1994.2 中藥學 知音出版社 137~140
80. 周煌、王筠默 1986. 中藥藥理 上海科學技術出版社 55~58,97~99
81. 趙亦成、蔣紀洋 1995. 淄博本草 中國中醫藥出版社 394~620

82. 新編中藥大辭典(下) 1978.9 新文豐出版公司 133~137
83. 全國中草藥匯編 1975.9 全國中草藥匯編編寫組編 北京 759~761
84. 許鴻源等 1985.1 簡明藥材學 新醫藥出版社 120~121
85. 黃泰康主編 1994.4 常用中藥成分與藥理手冊 中國醫藥科技出版社 1569~1574
86. 中藥藥理(下篇) 1988.10 彥欣中西醫藥學術研習中心 弘祥出版社 130~133
87. Kubo m., Matsuda H., Tanaka M., et al. 1984. Studies on scutellariae radix .  
Anti-arthritic and anti-inflammatory actions of methanolic extract and flavonoid components from Scutellariae radix. *Chem. Pharm. Bull.* 32,2724~2729
88. Yoshiyuki K., Michnori K., Kimiyo K. et al. 1982. Studies on scutellariae radix .  
Effects on ethanol induced hyperlipemia and lipolysis in isolated fat cells. *Chem. Pharm. Bull.* 30,219~222
89. Yoshiyuki K., Michnori K., Tadato T. et al. 1981. Studies on scutellariae radix .  
Effects on metabolism in serum, liver and fat cell of rats. *Chem. Pharm. Bull.* 19,2308~2312
90. Yoshiyuki K., Michnori K., Tadato T. et al. 1981. Studies on scutellariae radix .  
Effects on lipid peroxidation in rat liver. *Chem. Pharm. Bull.* 19,2610~2617
91. Kubo M., Matsuda H., Tani T. et al. 1985. Studies on scutellariae radix .  
Anti-thrombic actions of various flavonoids from Scutellariae radix. *Chem. Pharm. Bull.* 33,2411~2415
92. Butenko I.G., Gladchenko S.V., Galushko S.V. 1993. Anti-inflammatring properties and inhibition of leukotriene C4 biosynthesis in vitro by flavonoid baicalein from scutellariae baicaleinsis GEORGI roots. *Agents & actions* 39,c49~51
93. Nyby M.D., Sasaki M., Ideguchi Y. et al. 1996. Platelet lipoxxygenase inhibitors attenuate thrombin and thromboxane minetic induces intracellular calcium mobilization and platelet aggregation. *J. Pharmacol. Experim. Therap.* 278,503~509
94. Miyahara M., Ohtaka H., Katayama H. et al. 1993. Structure-activity relationship of flavonoids in suppressing rat liver lipid peroxidation. *Yakugaku-Zasshi.* 113,133~154
95. Gao D., Sakurai K., Chen J. et al. 1995. Inhibition of microsomal lipid peroxidation by baicalein: a possible formation of iron-baicalein complex. *Biochem. Mol. Biol.*

- Internat.* 39,215~225
96. Gao D., Sakurai K., Chen J. et al. 1995. Protection by baicalein against ascorbic acid-induced lipid peroxidation of rat liver microsomes. *Rear. Communi. Mol. Pathol. Pharmac.* 90,130~114
97. Yano H., Mizoguchi A., Fukuda K. et al. 1994. The herbal medicine Sho-saiko-to inhibits proliferation of cancer cell line by inducing apoptosis and arrest at the G0/G1 phase. *Cancer Reasearch* 54(2),448~454
98. 中藥毒理學 1989.9 啟業書局 23~24
99. 胡敏秀 1997.6 黃芩有效成分黃芩素在家兔之生物藥劑學研究  
(Biopharmaceutical studies of baicalein in rabbits) 中國醫藥學院中國藥學研究所藥學碩士論文
100. 王浴生主編 1983.8 中藥藥理與應用 北京科學技術出版社 956~965
101. Dasso M. & Newport J.W. 1990. Completion of DNA replication is monitored by a feedback system that controls the initiation of mitosis in vitro: Studies in *Xenopus*. *cell* 61,811~823
102. Norbury C. & Nurse D. 1993. Animal cell cycles and their control. *Ann. Rev. Biochem.* 61,441~470
103. Murray A.W., Solomon M.J., Kirschner M.W. 1989. The role of synthesis and degradation in the control of maturation promoting factor activity. *Nature* 339,280~286
104. Nurse P. 1990. Universal control mechanism regulating cell cycle timing of M-phase. *Nature* 344,503~508
105. Gerring S.L., Spencer F., Hieter P. 1990. The CHL1(CTF1) gene product of *S. cerevisiae* is important for chromosome transmission and normal cell cycle progression in G2/M. *EMBO J.* 9,4347~4358
106. Poo Y.C., Yamashita K., Adaczewski J. et al. 1993. The cdc2-related protein p40<sup>mo15</sup> is the catalytic subunit of a protein kinase that can activate p33<sup>cdk2</sup> and p34<sup>cdc2</sup>. *EMBD J.* 12,3123~3132
107. Krek W. & Nigg EA. 1991. Differential phosphorylation of vertebrate p34<sup>cdc2</sup> kinase at the G1/S and G2/M transitions of the cell cycle: Identification of major phosphorylation site. *EMBO J.* 10,305~316
108. Baldin V., Luskas J., Marcote M.J. et al. 1993. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. *Genes Dev.* 7,812~821
109. Harper J.W., Adami G.R., Wei N. et al. 1993. The p21 Cdk-interacting protein CIP1 is

- a potent inhibitor of G1 cyclin-dependent kinases. *Cell* 75,805~816
- 110.Koff A., Ohtsuki M., Polyas K. 1993. Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF- $\beta$ . *Science* 260,536~539
- 111.Paagano M. & Draetta G 1991. Cyclin A, cell cycle control and oncogenesis. *Prog. Growth Factor Res.* 3,267~277
- 112.Featherstone C. & Russell P. 1991. Fission yeast p107<sup>wee1</sup> mitotic inhibitor is a tyrosine/serine kinase. *Nature* 349,808~811
- 113.Glotzer M., Murray A.W. , Kirschner M.W. 1991. Cyclin is degraded by the ubiquitin pathway. *Nature* 349,132~138
- 114.Serrano M., Gomez-Lahoz E., Depinho R.A. et al. 1995. Inhibition of Ras-induced proliferation and cellular transformation by p16<sup>INK4</sup>. *Science* 207,249~252
- 115.Richards P.S., Saba T.M., Del Vecchio P.J. et al. 1986. Matrix fibronectin disruption in association with altered endothelial cell adhesion induced by activated polymorphonuclear leukocytes. *Exp. Mol. Pathol.* 45,1~21
- 116.李 宥 萱 1998. Inhibitory mechanisms of 2-phenyl-4-quinolone and 1,3,6,7-tetrahydroxyxanthone on serotonin-induced rat heart endothelial cells permeability 中國醫藥學院藥物化學研究所博士論文
- 117.Hämmerle H., Betz E., Herr D. 1991. Human endothelial cells are stimulated and vascular smooth muscle cells are inhibited in their proliferation and migration by heparins. *Vaso.* 20,207~214
- 118.Kyo R., Nakahata N., Sakakibara I., et al. 1998. Baicalin and baicalein, constituents of an important medicinal plant, inhibit intracellular Ca<sup>2+</sup> elevation by reducing phospholipase C activity in C6 rat glioma cells. *J. Pharm. Pharmacol.* 50,1179~1182
- 119.Tricoli J.V., Sahai B.M., Mc Lormick P.J. et al. 1985. DNA topoisomerase and activities during cell proliferation and the cell cycle in cultured mouse embryo fibroblast (C<sub>3</sub>H<sub>10</sub> T1/2) cells. *Exp. Cell Res.* 158,1~14
- 120.Austin C.A., Plael S., Ono K. et al. 1992. Site-specific DNA cleavage by mammalian DNA topoisomerase induced by novel flavone and catechin derivatives. *Biochem. J.* 282,883~889
- 121.Matsuzaki Y., Kurokawa N., Terai S., et al. 1996. Cell death induced by baicalein in human hepatocellular carcinoma cell lines. *Jpn. J. Cancer Res.* 87,170~177
- 122.Tomoo I. & Edwin K.J. 1999. Strong antiproliferative effects of baicalein in cultured rat hepatic stellate cells. *Eur. J. Pharmacol.* 378,129~135
- 123.Majno G. & Jois I. 1995. Apoptosis, oncosis, and necrosis. An overview of cell death.



*Am. J. Pathol.* 146,3~15

124. Kerr J.F., Winterford C.M., Harmon B.V. 1994. Apoptosis, It's significance in cancer and cancer therapy. *Cancer* 73,2013~2026
125. Yoshino M. & Murakami K 1998. Interaction of iron with polyphenolic compounds: Application to antioxidant characterization. *Analytical Biochemistry* 257,40~44
126. Shaw S., Naegeli P., Etter J.D., et al. 1995. Role of intracellular signalling pathways in hydrogen peroxide-induced injury to rat glomerular mesangial cells. *Clin. Exper. Pharm. Physiol.* 22,924~933
127. Dayuan G., Riichi T., Hitoshi M., et al. 1998. Protective effects of baicalein against cell damage by reactive oxygen species. *Chem. Pharm. Bull.* 46,1383~1387
128. Ewen M.E., Sluss H.K., Whitehouse L.L., et al. 1993. TGF $\beta$  effects on expression of G1 cyclins and cyclin-dependent protein kinase. *Proc. Natl. Acad. Sci. USA* 90,10315~10319
129. Geng Y. & Weinberg R.A. 1993. Transforming growth factor  $\beta$  effects on expression of G1 cyclins and cyclin-dependent protein kinase. *Proc. Natl. Acad. Sci. USA* 90,10315~10319
130. Dulic V., Kufmann W.K., Wilson S.J., et al. 1994. p53-dependent inhibition of cyclin-dependent kinase activity in human fibroblasts during-rduced G1 arrest. *Cell* 76,1013~1023
131. Nasmyth K. 1996. Viewpoint: putting the cell cycle in order. *Science* 274,1643~1645
132. Matsushime H., Ewen M.E., Strom D.K., et al. 1992. Identification and properties of an atypical catalytic subunit (p34<sup>PSK</sup>-J3/cdk4) for mammalian D type G1 cyclins. *Cell* 71,323~334
133. Nigg E.A. 1995. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. *BioEssays* 17,471~480
134. Sherr C.J. 1993. Mammalian G1 cyclins. *Cell* 73,1059~1065
135. Pines J. 1992. Cell proliferation and control. *Curr. Opin. Cell Biol.* 4,144~148
136. Matsushime H., Roussel M.F., Ashmun R.A., et al. 1991. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle. *Cell* 65,701~713
137. Draetta G. & Beach D. 1988. Activation of cdc2 protein kinase during mitosis in human cells: cell cycle-dependent phosphorylation and subunit rearrangement. *Cell* 54,17~26
138. Pines J. 1993. Cyclins and cyclin-dependent kinases: take your partners. *Trend. Biochem. Scien.* 18,195~197
139. Quelle D.E., Ashmun R.A., Shurtleff S.A. et al. 1993. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. *Gene Dev.* 7,1559~1571
140. Jiang W., Kahn S.M., Zhou P., et al. 1993. Overexpression of cyclin D1 in rat

- fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. *Oncogene* 8,3447~3457
141. Resnitzky D., Gossen M., Bujard H., et al. 1994. Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. *Mol. Cell. Biol.* 14,1669~1679
  142. Ohtani K., DeGregori J., Nevins J.R. 1995. Regulation of the cyclin E gene by transcription factor E2F1. *Proc. Natl. Acad. Sci. USA* 92,12146~12150
  143. Weinberg R.A. 1995. The retinoblastoma protein and cell cycle control. *Cell* 81,323~330
  144. Murray A.W. & Kirschner M.W. 1989. Cyclin synthesis drives the early embryonic cell cycle. *Nature* 339,275~280
  145. Sherr C.J. & Roberts J.M. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. *Genes Dev.* 9,1149~1163
  146. Zhang H., Hannon G.J., Beach D. 1994. p21-containing cyclin kinases exist in both active and inactive states. *Genes Dev.* 8,1750~1758
  147. Waga S., Hannon G.J., Beach D., et al. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. *Nature* 369,574~578
  148. Flores-Rozas H., Kelman Z., Dean F.B., et al. 1994. Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. *Proc. Natl. Acad. Sci. USA* 91,8655~8659
  149. El-Deiry W.S., Tokino T., Velculescu V.E., et al. 1993. WAF1, a potential mediator of p53 tumor suppression. *Cell* 75,817~825
  150. Bargonetti J., Reynisdottir I., Friedman P.N. 1992. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53. *Genes Dev.* 6,1886~1898
  151. Zambetti G.P., Bargonetti J., Walker K., et al. 1992. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element. *Genes Dev.* 6,1143~1152
  152. Prives C. 1993. Doing the right thing: feedback control and p53. *Curr. Opin. Cell Biol.* 5,214~218
  153. Stromblad S., Becker J.C., Yebra M., et al. 1996. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. *J. Clin. Invest.* 98,426~433
  154. Halevy O., Novitch B.G., Spicer D.B., et al. 1995. Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. *Science* 267,1018~1021
  155. Skapek S.X., Rhee J., Spicer D.B., et al. 1995. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. *Science* 267,1022~1024
  156. Liu M., Lee M.H., Cohen M., et al. 1996. Transcription activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line

U937. *Gene Dev.* 10,142~153

157. Hannon G.J. & Beach D. 1994. p15<sup>INK4B</sup> is a potential effector of TGF- $\beta$ -induced cell cycle arrest. *Nature* 371,257~259
158. Peter M. & Herskowitz I. 1994. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. *Cell* 79,181~184
159. Cobrinik D., Dowdy S.F., Hinds P.W., et al. 1992. The retinoblastoma protein and the regulation of cell cycling. *Trend in Biochem. Scien.* 17,312~315
160. Hurford R.K., Cobrinik D., Lee M.H., et al. 1997. pRb and p107/p130 are required for the regulated expression of different sets of E2F responsive genes. *Gene Dev.* 11,1447~1463
161. Ruoslahti E. & Giancotti F.G. 1989. Integrins and tumor cell dissemination. *Cancer Cell* 1,119~126
162. Ingber D.E. & Folkman J. 1989. How does extracellular matrix control capillary morphogenesis? *Cell* 59,803~805
163. Edelman G.M. & Crossin K.L. 1991. Cell adhesion molecules: Implications for a molecular histology. *Annu. Rev. Biochem.* 60,155~190
164. Boucant J.C., Darribere T., Poole T.J., et al. 1984. Biologically active synthetic peptides as probes of embryonic development: A competitive peptide inhibitor of fibronectin function inhibits gastrulation in amphibian embryos and neural crest cell migration. *J. Cell Biol.* 99,1822~1830
165. Peng W., James B.H., Stuart K.W., et al. 1994. Integrin-binding peptide in solution inhibits or enhance endothelial cell migration, predictably from cell adhesion. *Ann. Biomed. Engin.* 22,144~152
166. Giraux J.L., Matou S., Bros A., et al. 1998. Modulation of human endothelial cell proliferation and migration by fucoidan and heparin. *Eurp. J. Cell Biol.* 77,352~359
167. Humphries M.J., Olden K., Yamad K.M. 1986. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. *Science* 233,467~470
168. Nicosia R.F. & Bonanno E. 1991. Inhibition of angiogenesis in vitro by arg-gly-asp containing synthetic peptide. *Am. J. Pathol.* 138,829~833
169. Ausprunk D.H. & Fokman J. 1977. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during angiogenesis. *Microva. Res.* 14,53~65
170. Montesano R., Vassalli J.D., Baird A., et al. 1986. Basic fibroblast growth factor induces angiogenesis in vitro. *Proc. Natl. Acad. Sci. USA.* 83,7297~7301
171. Moscatelli D. & Rifkin D.B. 1988. Membrane matrix localization of proteases: a common theme in tumor invasion and angiogenesis. *Biochem. Biophys. Acta.* 948,67~85
172. Weidner N. 1991. Tumor angiogenesis and metastasis: correlation in invasive breast

- carcinoma. *N. Engl. J. Med.* 324,1~8
173. Deepa T., Anoop K.S., Gurmel S.S., et al. 1998. Inhibition of Angiogenic differentiation of human umbilical vein endothelial cells by curcumin. *Cell grow. Different.* 9,305~312
174. Kleinman H.K., McGarrey M.L., Liotta A., et al. 1982. Isolation and characterization of type procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. *Biochem.* 21,6188~6193
175. Mukherjee G., Rasmusson B., Linner J.G., et al. 1998. Organization and mobility of CD11b/CD18 and targeting of superoxide on the surface of degranulated human neutrophils. *Arch. Biochem. Biophys.* 357,164~172
176. Sampath R., Gallagher P.J., Pavalko F.M. 1998. Cytoskeletal interactions with the leukocyte integrin beta2 cytoplasmic tail. Activation-dependent regulation of associations with talin and alpha-actinin. *J. Biol. Chem.* 273,33588~33594
177. Kucik D.F., Dustin M.L., Miller J.M., et al. 1996. Adhesion-activating phorbol ester increases the mobility of leukocyte integrin LFA-1 in cultured lymphocytes. *J. Clin. Invest.* 97,2139~2144
178. Luna E.J. & Hitt A.L. 1992. Cytoskeleton-plasma membrane interactions. *Science* 258,955~964
179. Clark E.A. & Brugge J.S. 1995. Integrins and signal transduction pathways: The road taken. *Science* 268,233~239
180. Kiyoko U. & Masayuki M. 1999. Stress fiber networks in sinus endothelial cells in the rat spleen. *Anat. Rec.* 254,22~27
181. Hynes R.O. 1992. Integrins: Versatility, modulation, and signaling in cell adhesion. *Cell* 69,11~25
182. Arroyo A.G., Campanero M.R., Sanchez M.P., et al. 1994. Induction of tyrosine phosphorylation during ICAM-3 and LFA-1 mediated intercellular adhesion, and its regulation by the CD45 tyrosine phosphatase. *J. Cell Biol.* 126,1277~1286
183. Takahashi M.O., Takahashi Y., Iida K., et al. 1999. Growth hormone stimulates tyrosine phosphorylation of focal adhesion kinase and actin stress fiber formation in human osteoblast-like cells, Saos2. *Biochem. Biophys. Res. Communi.* 263,100~106
184. Staffan S. & David A.C. 1996. Cell adhesion and angiogenesis. *Cell Biology* 6,462~468
185. Jocksch B., Bubeck P., Giehl K., et al. 1995. The molecular architecture of focal adhesions. *Annu. Rev. Biol.* 11,379~416
186. Jones S. & Thornton J.M. 1996. Principles of protein-protein interactions. *Proc. Natl. Acad. Sci. USA* 93,13~20
187. Buckley C.D., Rainger G.E., Bradfield P.F., et al. 1998. Cell adhesion: more than just glue. *Mol. Membr. Biol.* 15,167~176
188. Dedhar S. 1999. Integrins and signal transduction. *Curr. Opin. Hematol.* 6,37~43

189. Meredith J.E., Fazeli B., Schwartz M.A. 1993. *Mol. Biol. Cell* 4,953~961
190. Re F., Zanetti A., Sironi M., et al. 1994. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells. *J. Cell Biol.* 127,537~546
191. Hynes R.O. 1987. Integrins: a family of cell surface receptors. *Cell* 48,549~554
192. Albelda S.M. & Buck C.A. 1990. Integrins and other cell adhesion molecules. *FASEB J.* 4,2868~2880
193. Lasky L.A. 1992. Selectins: interpreters of cell-specific carbohydrate information during inflammation. *Science* 258,964~969
194. Takeichi M. 1987. Cadherins: a molecular family essential for selective cell-cell adhesion and animal morphogenesis. *Trends Genet.* 3,213~217
195. Brummendorf T. & Rathjen F.G. 1995. Cell adhesion molecules: immunoglobulin superfamily protein. *Prof.* 2,293~1108
196. Löster K. & Horstkorte R. 2000. Enzymatic quantification of cell-matrix and cell-cell adhesion. *Micron* 31,41~53
197. Yoshiyuki K., Nobutoshi M., Hiromichi O. 1997. Effect of baicalein isolated from *Scutellaria baicalensis* on interleukin 1 - and tumor necrosis factor -induced adhesion molecule expression in cultured human umbilical vein endothelial cells. *J. Ethnopharmacol.* 57,63~67
198. Yoshiyuki K., Kumi Y., Nobutoshi M. et al. 1997. Effects of flavonoids isolated from *Scutellariae Radix* on the production of tissue-type plasminogen activator and plasminogen activator inhibitor-1 induced by thrombin and thrombin receptor agonist peptide in cultured human umbilical vein endothelial cells. *J. pharm. Pharmacol.* 49,816~822
199. Cheng Y.F. & Kramer R.H. 1989. Human microvascular endothelial cells express integrin-related complexes that mediate adhesion to the extracellular matrix. *J. Cellu. Physiol.* 139,275~286
200. Ruoslahti E. & Piersbacher M.D. 1987. New perspectives in cell adhesion, RGD and integrins. *Science* 238,491~497
201. Ruoslahti E. 1996. RGD and other recognition sequences for integrins. *Annu. Rev. Cell Dev. Biol.* 12,697~715